Praxis Seizure Drug Vormatrigine Shows Strong Efficacy in Phase 2 Trial

Vormatrigine, developed by Praxis Precision Medicines, achieved a 56.3% median reduction in seizure frequency over 8 weeks in patients with focal onset seizures, according to topline Phase 2 RADIANT study results1234.

22% of patients experienced complete seizure freedom in the last 28 days of treatment234.

Over 54% of patients achieved a 50% reduction in seizure frequency after just one week of therapy1234.

The drug was generally well tolerated, although approximately 23% of patients discontinued the trial1.

Analysts described vormatrigine's efficacy as surpassing that of leading competitors such as Xcopri (55.6%) and XEN-1101 (52.8%)3.

Vormatrigine offers advantages including rapid effect, no titration, once-daily dosing, and no food requirements4.

Praxis plans to complete a pivotal Phase 2/3 POWER1 study by the end of 2025 and will present further data at major epilepsy conferences4.

Sources:

1. https://www.fiercebiotech.com/biotech/praxis-tracks-reduction-seizures-plans-phase-23-study

2. https://www.ainvest.com/news/praxis-precision-medicine-vormatrigine-shows-promising-mid-stage-trial-results-anti-seizure-therapy-2508/

3. https://www.biospace.com/drug-development/praxis-seizure-drug-demonstrates-impressive-efficacy-in-mid-stage-trial

4. https://www.stocktitan.net/news/PRAX/praxis-precision-medicines-announces-positive-best-in-disease-8zpczmczhae2.html